As we reported back in early March of 2010, Merck had struck a deal with Teva to delay the introduction of a generic temozolomide cancer fighting drug until August 2013. Merck sells temozolomide under the brand name Temodar®. My guess back then was that Merck saved something like $500 million by cutting the Teva pay to delay deal.
Very recently, the delay ended -- per Zacks Investment Services, just now.
. . . .Teva and Perrigo have a collaboration agreement for generic Temodar under which Teva will manufacture, market and distribute the product in the U.S. while both companies will share the cost and profit on the sales of the generic version of the drug in the U.S.
As Teva was the first to file for a generic version, it will enjoy 180 days marketing exclusivity.
We note that Temodar is indicated for the treatment of adults suffering from newly diagnosed glioblastoma multiforme along with radiotherapy and subsequent maintenance.
Temodar is also approved to treat refractory anaplastic astrocytoma in patients whose disease has progressed while being treated with a regimen containing nitrosourea and procarbazine
. . .Temodar generated sales of $423 million in the U.S. in 2012. We remind investors that Temodar lost patent exclusivity in the EU in 2009. . . .
So it goes.
3 comments:
So of that $ amount, do you know what the division is between the oral and I.V. formulations?
It could be interesting as the generation of the IV formulation was quite difficult and something that Merck can hold onto for a little while longer.
I honestly have no idea -- will check IMS tomorrow. . . should be listed that way -- in the subscription side of the database. . .
Thanks, and. . .
Namaste
As a follow up and a bit late, there was this back in June:
http://www.reuters.com/article/2013/06/07/us-forest-icahn-idUSBRE9560HJ20130607
Can Freddie be far behind?
Post a Comment